About MIIST Therapeutics

MIIST Therapeutics develops a pulmonary drug delivery system that produces sterile aqueous particles 50% smaller than traditional inhalers, allowing for rapid absorption in the peripheral lung and peak plasma levels within seconds. This technology addresses the need for immediate relief in acute conditions, such as smoking cessation and migraines, where existing therapies take too long to be effective.

```xml <problem> Existing treatments for acute conditions like smoking cessation and migraines often take too long to provide relief, as they rely on slow absorption through the central lung or oral administration. Traditional inhalers produce particles too large to reach the peripheral lung, where rapid drug absorption can occur. This delay in relief can lead to relapse in addiction cases and prolonged suffering for migraine patients. </problem> <solution> Miist Therapeutics is developing a pulmonary drug delivery system that generates sterile aqueous particles 50% smaller than those produced by conventional inhalers. This allows for targeted delivery to the peripheral lung, enabling rapid absorption into the bloodstream and achieving peak plasma levels within seconds. By bypassing the slower absorption rates of the central lung and oral medications, Miist's technology aims to provide immediate relief for acute conditions. The platform is being applied to develop rapid-acting therapies for smoking cessation (MST01) and migraines (MST02). MST01 is clinically validated to eliminate 93% of a patient's cravings within 2 minutes and employs a programmed dosing protocol that automatically reduces the delivered dose by 1.1%, daily, over the course of a 12 week treatment. </solution> <features> - Inhaler produces particles that are 50% smaller for targeted delivery to the peripheral lung. - Rapid absorption into the bloodstream, achieving peak plasma levels in under 30 seconds. - Sterile aqueous particles produced using vibration, eliminating the need for heat. - MST01 (smoking cessation): Clinically validated to eliminate 93% of cravings within 2 minutes. - MST01 (smoking cessation): Programmed dosing protocol for gradual nicotine reduction over 12 weeks. - MST02 (migraine): In preclinical development with the potential to deliver peak migraine relief within 5 minutes. </features> <target_audience> The primary target audience includes individuals seeking immediate relief from acute conditions such as nicotine cravings and migraines, as well as healthcare providers looking for faster-acting treatment options. </target_audience> ```

What does MIIST Therapeutics do?

Where is MIIST Therapeutics located?

MIIST Therapeutics is based in Alameda, United States.

When was MIIST Therapeutics founded?

MIIST Therapeutics was founded in 2019.

Location

Alameda, United States

Founded

2019

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

MIIST Therapeutics

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

mymiist.com LinkedIn Profile

Founded 2019 – Alameda, United States

Funding

No funding information available.

Team

No team information available.

Company Description

Problem

Existing treatments for acute conditions like smoking cessation and migraines often take too long to provide relief, as they rely on slow absorption through the central lung or oral administration. Traditional inhalers produce particles too large to reach the peripheral lung, where rapid drug absorption can occur. This delay in relief can lead to relapse in addiction cases and prolonged suffering for migraine patients.

Solution

Miist Therapeutics is developing a pulmonary drug delivery system that generates sterile aqueous particles 50% smaller than those produced by conventional inhalers. This allows for targeted delivery to the peripheral lung, enabling rapid absorption into the bloodstream and achieving peak plasma levels within seconds. By bypassing the slower absorption rates of the central lung and oral medications, Miist's technology aims to provide immediate relief for acute conditions. The platform is being applied to develop rapid-acting therapies for smoking cessation (MST01) and migraines (MST02). MST01 is clinically validated to eliminate 93% of a patient's cravings within 2 minutes and employs a programmed dosing protocol that automatically reduces the delivered dose by 1.1%, daily, over the course of a 12 week treatment.

Features

Inhaler produces particles that are 50% smaller for targeted delivery to the peripheral lung.

Rapid absorption into the bloodstream, achieving peak plasma levels in under 30 seconds.

Sterile aqueous particles produced using vibration, eliminating the need for heat.

MST01 (smoking cessation): Clinically validated to eliminate 93% of cravings within 2 minutes.

MST01 (smoking cessation): Programmed dosing protocol for gradual nicotine reduction over 12 weeks.

MST02 (migraine): In preclinical development with the potential to deliver peak migraine relief within 5 minutes.

Target Audience

The primary target audience includes individuals seeking immediate relief from acute conditions such as nicotine cravings and migraines, as well as healthcare providers looking for faster-acting treatment options.